<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822792</url>
  </required_header>
  <id_info>
    <org_study_id>RSCD2020002</org_study_id>
    <nct_id>NCT04822792</nct_id>
  </id_info>
  <brief_title>Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT</brief_title>
  <acronym>PRESCIENT</acronym>
  <official_title>Pan-cancer Early-stage Detection by Liquid Biopsy in Peripheral Blood: a Multi-center, Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou Burning Rock Dx Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by&#xD;
      combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers.&#xD;
      Blood RNA markers will also be evaluated. The study will enroll approximately 11879&#xD;
      participants, including participants with malignancies or benign diseases, and healthy&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of early detection of 22 types of cancers and Tissue of origin (TOO) accuracy of a cfDNA methylation-based model, in combination with serum tumor markers</measure>
    <time_frame>22 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of a cfDNA methylation-based model combined with serum tumor markers in participants with cancers or benign diseases</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of serum tumor markers, cfDNA methylation-based model, and a cfDNA methylation-based model combined with serum tumor markers, in participants with cancers and healthy participants</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of early detection of cancer in different stages</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">11879</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer Arm</arm_group_label>
    <description>Participants with new diagnosis of cancer, from whom blood samples will be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benign Diseases Arm</arm_group_label>
    <description>Participants with benign diseases corresponding to the tumor types in the Cancer Arm, from whom blood samples will be collected</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Arm</arm_group_label>
    <description>Participants without known presence of malignancies or benign disease, from whom blood samples will be collected</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Multi-cancer early detection test</intervention_name>
    <description>Blood collection and multi-cancer early detection test</description>
    <arm_group_label>Benign Diseases Arm</arm_group_label>
    <arm_group_label>Cancer Arm</arm_group_label>
    <arm_group_label>Healthy Arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible participants will be re recruited from medical centers and assigned into three&#xD;
        arms, including participants with new diagnosis of malignancies or corresponding benign&#xD;
        diseases, and participants without the presence of malignancies or benign diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for All the Participants:&#xD;
&#xD;
          -  Ability to provide a written informed consent&#xD;
&#xD;
          -  40-75 years old&#xD;
&#xD;
        Exclusion Criteria for All the Participants:&#xD;
&#xD;
          -  Inability to comply with study procedures&#xD;
&#xD;
          -  Pregnancy or lactating women&#xD;
&#xD;
          -  Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow&#xD;
             transplant or stem cell transplant&#xD;
&#xD;
          -  Recipients of blood transfusion within 7 days prior to study blood draw&#xD;
&#xD;
          -  Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to&#xD;
             diseases other than cancer&#xD;
&#xD;
        Inclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Confirmed diagnosis or suspicious cases of one of the 22 types of malignancies within&#xD;
             42 days prior to study blood draw&#xD;
&#xD;
          -  No prior or ongoing anti-cancer therapy (local or systematic) prior to study blood&#xD;
             draw&#xD;
&#xD;
        Exclusion Criteria for Cancer Arm Participants:&#xD;
&#xD;
          -  Known prior diagnosis of malignancies&#xD;
&#xD;
          -  Other current malignant diseases or multiple primary tumors&#xD;
&#xD;
          -  No confirmed diagnosis of cancer by histopathological or radiological assessments&#xD;
             within 42 days of study blood draw, or diagnosis of a benign disease by&#xD;
             histopathological assessments, or inability to characterize whether the lesion is&#xD;
             malignant or benign&#xD;
&#xD;
          -  Non-small-cell lung cancer patients with ground-class nodularity by radiological&#xD;
             examination&#xD;
&#xD;
        Inclusion Criteria for Benign Diseases Arm Participants:&#xD;
&#xD;
          -  Confirmed diagnosis of benign diseases corresponding to the tumor types in the Cancer&#xD;
             Arm by histopathological or radiological assessments within 90 days prior to study&#xD;
             blood draw&#xD;
&#xD;
          -  No prior treatment of benign diseases prior to study blood draw&#xD;
&#xD;
        Exclusion Criteria for Benign Diseases Arm Participants:&#xD;
&#xD;
          -  History of malignancies&#xD;
&#xD;
          -  Current malignancies or precancerous lesions&#xD;
&#xD;
          -  No confirmed diagnosis of a benign disease by radiological, endoscopic or&#xD;
             histopathological assessments within 42 days of study blood draw, or inability to&#xD;
             characterize whether the lesion is malignant or benign&#xD;
&#xD;
        Inclusion Criteria for Non-tumor (Healthy) Arm Participants:&#xD;
&#xD;
          -  No cancer-related symptoms or discomfort within 30 days prior to study blood draw&#xD;
&#xD;
          -  No clinically significant finding by LDCT or ultrasound&#xD;
&#xD;
          -  No clinically significant finding by breast ultrasound or Molybdenum Target&#xD;
             Mammography Detection, or Thinprep cytologic test (TCT) detection for female&#xD;
             participants&#xD;
&#xD;
          -  No active hepatitis B or hepatitis C infection&#xD;
&#xD;
        Exclusion Criteria for Non-tumor (Healthy) Arm Participants:&#xD;
&#xD;
          -  Prior or ongoing treatment of cancer within 3 years prior to study blood draw&#xD;
&#xD;
          -  Clinically significant or uncontrolled comorbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiachen Xu, M.D.</last_name>
    <phone>+86-010-87788029</phone>
    <email>XJCwelcome@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shangli Cai, Ph.D.</last_name>
    <phone>+86-021-61631938</phone>
    <email>shangli.cai@brbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiachen Xu, M.D.</last_name>
      <phone>+86-10-87788029</phone>
      <email>XJCwelcome@126.com</email>
    </contact>
    <investigator>
      <last_name>Jie Wang, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>May 29, 2021</last_update_submitted>
  <last_update_submitted_qc>May 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Liquid biopsy</keyword>
  <keyword>Cell-free DNA (cfDNA)</keyword>
  <keyword>Early detection</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

